Dan Heller, PhD & Douglas A. Levine, MD

Dan Heller, PhD & Douglas A. Levine, MD

About Project

An implantable biomarker nanosensor for early-stage ovarian cancer detection


Drs. Heller and Levine developed a biosensor that can be implanted into at-risk women to monitor the development of ovarian cancer in real time. The sensor can also be used to track treatment response, which would be invaluable since a consistent bane of cancer therapeutics is knowing which patients will respond to which treatments and which will not. Lastly, the sensor will scan for signs of disease recurrence. Their first round of studies demonstrated that the sensor can in fact detect ovarian cancer biomarkers in patient fluids; now they intend to determine the earliest time point at which they can measure cancer and optimize the sensor to prepare for clinical trials.

Back to Current Research